Search research articles
Contact Us
Filters
Showing results (121-130 of 134) with videos related to
Page
of 14
Sort By:
Cancer Discovery
|
May 17, 2020
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of <i>EGFR</i> Exon 20 Insertion-Driven NSCLC
Jiyeon Yun, Soo-Hwan Lee, Seok-Young Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report
Hidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.
Cancer Research Communications
|
June 25, 2024
Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma
Sun M Lim, Seong-San Kang, Dong K Kim, et al.
Nature Medicine
|
September 14, 2023
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
Byoung Chul Cho, Dong-Wan Kim, Alexander I Spira, et al.
Pediatric Research
|
February 8, 2023
Tobacco smoke exposure, the lower airways microbiome and outcomes of ventilated children
Matthew K Leroue, Kayla M Williamson, Paul C Curtin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 31, 2020
Low Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Among Pregnant and Postpartum Patients With Universal Screening in Seattle, Washington
Sylvia M LaCourse, Alisa Kachikis, Michela Blain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2026
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study
Barbara Burtness, Ari J Rosenberg, Benoit Calderon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2025
Amivantamab Plus Lazertinib in Atypical <i>EGFR</i>-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2
Pascale Tomasini, Yongsheng Wang, Yongsheng Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA
Se-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 18, 2025
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
Matthew G Krebs, Byoung Chul Cho, Sandrine Hiret, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 134) with videos related to
Sort By:
Page
of 14
Cancer Discovery
|
May 17, 2020
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of <i>EGFR</i> Exon 20 Insertion-Driven NSCLC
Jiyeon Yun, Soo-Hwan Lee, Seok-Young Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report
Hidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.
Cancer Research Communications
|
June 25, 2024
Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma
Sun M Lim, Seong-San Kang, Dong K Kim, et al.
Nature Medicine
|
September 14, 2023
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
Byoung Chul Cho, Dong-Wan Kim, Alexander I Spira, et al.
Pediatric Research
|
February 8, 2023
Tobacco smoke exposure, the lower airways microbiome and outcomes of ventilated children
Matthew K Leroue, Kayla M Williamson, Paul C Curtin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 31, 2020
Low Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Among Pregnant and Postpartum Patients With Universal Screening in Seattle, Washington
Sylvia M LaCourse, Alisa Kachikis, Michela Blain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2026
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study
Barbara Burtness, Ari J Rosenberg, Benoit Calderon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2025
Amivantamab Plus Lazertinib in Atypical <i>EGFR</i>-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2
Pascale Tomasini, Yongsheng Wang, Yongsheng Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA
Se-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 18, 2025
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
Matthew G Krebs, Byoung Chul Cho, Sandrine Hiret, et al.
Page
of 14